nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—bone cancer	0.639	1	CtDrD
Temsirolimus—CYP3A4—bone cancer	0.222	1	CbGaD
Temsirolimus—MTOR—leg—bone cancer	0.00196	0.201	CbGeAlD
Temsirolimus—MTOR—forelimb—bone cancer	0.00194	0.2	CbGeAlD
Temsirolimus—MTOR—hindlimb—bone cancer	0.00175	0.18	CbGeAlD
Temsirolimus—MTOR—appendage—bone cancer	0.0015	0.154	CbGeAlD
Temsirolimus—Pimecrolimus—CYP3A4—bone cancer	0.000788	0.314	CrCbGaD
Temsirolimus—Everolimus—CYP3A4—bone cancer	0.000788	0.314	CrCbGaD
Temsirolimus—Sirolimus—CYP3A4—bone cancer	0.000469	0.186	CrCbGaD
Temsirolimus—Tacrolimus—CYP3A4—bone cancer	0.000469	0.186	CrCbGaD
Temsirolimus—MTOR—connective tissue—bone cancer	0.000428	0.0441	CbGeAlD
Temsirolimus—FKBP1A—connective tissue—bone cancer	0.000385	0.0396	CbGeAlD
Temsirolimus—MTOR—tendon—bone cancer	0.000294	0.0303	CbGeAlD
Temsirolimus—MTOR—bone marrow—bone cancer	0.000285	0.0293	CbGeAlD
Temsirolimus—MTOR—spinal cord—bone cancer	0.000283	0.0292	CbGeAlD
Temsirolimus—FKBP1A—tendon—bone cancer	0.000264	0.0272	CbGeAlD
Temsirolimus—FKBP1A—bone marrow—bone cancer	0.000256	0.0264	CbGeAlD
Temsirolimus—FKBP1A—spinal cord—bone cancer	0.000255	0.0263	CbGeAlD
Temsirolimus—Blood creatinine increased—Epirubicin—bone cancer	0.000129	0.00146	CcSEcCtD
Temsirolimus—Dehydration—Epirubicin—bone cancer	0.000128	0.00145	CcSEcCtD
Temsirolimus—Skin disorder—Cisplatin—bone cancer	0.000128	0.00145	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000127	0.00144	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—bone cancer	0.000126	0.00143	CcSEcCtD
Temsirolimus—Anorexia—Cisplatin—bone cancer	0.000125	0.00142	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—bone cancer	0.000125	0.00142	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000124	0.0014	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—bone cancer	0.000123	0.00139	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—bone cancer	0.000122	0.00138	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000121	0.00137	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00012	0.00136	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—bone cancer	0.00012	0.00135	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—bone cancer	0.000119	0.00135	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—bone cancer	0.000119	0.00134	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—bone cancer	0.000119	0.00134	CcSEcCtD
Temsirolimus—Dysuria—Methotrexate—bone cancer	0.000119	0.00134	CcSEcCtD
Temsirolimus—Neutropenia—Methotrexate—bone cancer	0.000119	0.00134	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—bone cancer	0.000118	0.00134	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Methotrexate—bone cancer	0.000118	0.00134	CcSEcCtD
Temsirolimus—Dyspnoea—Cisplatin—bone cancer	0.000117	0.00133	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—bone cancer	0.000117	0.00132	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—bone cancer	0.000116	0.00131	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000115	0.0013	CcSEcCtD
Temsirolimus—Decreased appetite—Cisplatin—bone cancer	0.000114	0.00129	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—bone cancer	0.000114	0.00129	CcSEcCtD
Temsirolimus—Pneumonia—Methotrexate—bone cancer	0.000114	0.00129	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Cisplatin—bone cancer	0.000114	0.00129	CcSEcCtD
Temsirolimus—Infestation NOS—Methotrexate—bone cancer	0.000113	0.00128	CcSEcCtD
Temsirolimus—Infestation—Methotrexate—bone cancer	0.000113	0.00128	CcSEcCtD
Temsirolimus—Depression—Methotrexate—bone cancer	0.000113	0.00128	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—bone cancer	0.000113	0.00127	CcSEcCtD
Temsirolimus—Pain—Cisplatin—bone cancer	0.000113	0.00127	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000112	0.00127	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000112	0.00127	CcSEcCtD
Temsirolimus—Renal failure—Methotrexate—bone cancer	0.000111	0.00126	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—bone cancer	0.000111	0.00126	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—bone cancer	0.000111	0.00126	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—bone cancer	0.000111	0.00125	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—bone cancer	0.00011	0.00125	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—bone cancer	0.00011	0.00125	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—bone cancer	0.00011	0.00125	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—bone cancer	0.00011	0.00124	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—bone cancer	0.00011	0.00124	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—bone cancer	0.00011	0.00124	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—bone cancer	0.000108	0.00122	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—bone cancer	0.000108	0.00122	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—bone cancer	0.000107	0.00121	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—bone cancer	0.000107	0.00121	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—bone cancer	0.000107	0.00121	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—bone cancer	0.000106	0.0012	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—bone cancer	0.000106	0.0012	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—bone cancer	0.000106	0.0012	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000105	0.00119	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—bone cancer	0.000104	0.00118	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—bone cancer	0.000104	0.00118	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—bone cancer	0.000103	0.00117	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—bone cancer	0.000103	0.00117	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—bone cancer	0.000103	0.00117	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—bone cancer	0.000103	0.00116	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—bone cancer	0.000103	0.00116	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000102	0.00116	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—bone cancer	0.000102	0.00115	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—bone cancer	0.000101	0.00114	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—bone cancer	0.000101	0.00114	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—bone cancer	0.0001	0.00114	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—bone cancer	0.0001	0.00113	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—bone cancer	9.96e-05	0.00113	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—bone cancer	9.95e-05	0.00113	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—bone cancer	9.94e-05	0.00112	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—bone cancer	9.92e-05	0.00112	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—bone cancer	9.86e-05	0.00112	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—bone cancer	9.81e-05	0.00111	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—bone cancer	9.81e-05	0.00111	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	9.74e-05	0.00257	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—KIT—bone cancer	9.72e-05	0.00257	CbGpPWpGaD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—bone cancer	9.72e-05	0.0011	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—bone cancer	9.7e-05	0.0011	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—bone cancer	9.64e-05	0.00109	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—bone cancer	9.61e-05	0.00109	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—bone cancer	9.56e-05	0.00108	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—bone cancer	9.54e-05	0.00108	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—bone cancer	9.53e-05	0.00108	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—bone cancer	9.53e-05	0.00108	CcSEcCtD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—bone cancer	9.5e-05	0.00251	CbGpPWpGaD
Temsirolimus—Eye disorder—Methotrexate—bone cancer	9.5e-05	0.00107	CcSEcCtD
Temsirolimus—Asthenia—Cisplatin—bone cancer	9.44e-05	0.00107	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—bone cancer	9.44e-05	0.00107	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—bone cancer	9.43e-05	0.00107	CcSEcCtD
Temsirolimus—MTOR—TSH signaling pathway—JUN—bone cancer	9.43e-05	0.00249	CbGpPWpGaD
Temsirolimus—Urinary tract disorder—Epirubicin—bone cancer	9.39e-05	0.00106	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—bone cancer	9.37e-05	0.00106	CcSEcCtD
Temsirolimus—MTOR—Insulin Signaling—IGF1R—bone cancer	9.35e-05	0.00247	CbGpPWpGaD
Temsirolimus—Haematuria—Doxorubicin—bone cancer	9.35e-05	0.00106	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—bone cancer	9.35e-05	0.00106	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—bone cancer	9.33e-05	0.00105	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—bone cancer	9.25e-05	0.00105	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—bone cancer	9.22e-05	0.00104	CcSEcCtD
Temsirolimus—MTOR—Regulation of Telomerase—JUN—bone cancer	9.21e-05	0.00243	CbGpPWpGaD
Temsirolimus—Sinusitis—Doxorubicin—bone cancer	9.2e-05	0.00104	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—bone cancer	9.18e-05	0.00104	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—bone cancer	9.16e-05	0.00104	CcSEcCtD
Temsirolimus—Chills—Methotrexate—bone cancer	9.12e-05	0.00103	CcSEcCtD
Temsirolimus—Diarrhoea—Cisplatin—bone cancer	9e-05	0.00102	CcSEcCtD
Temsirolimus—MTOR—CDC42 signaling events—JUN—bone cancer	9e-05	0.00238	CbGpPWpGaD
Temsirolimus—Erythema multiforme—Epirubicin—bone cancer	8.99e-05	0.00102	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—BRAF—bone cancer	8.93e-05	0.00236	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—BRAF—bone cancer	8.93e-05	0.00236	CbGpPWpGaD
Temsirolimus—Mental disorder—Methotrexate—bone cancer	8.91e-05	0.00101	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—bone cancer	8.89e-05	0.00101	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—bone cancer	8.85e-05	0.001	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—bone cancer	8.85e-05	0.001	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—bone cancer	8.83e-05	0.000999	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—bone cancer	8.82e-05	0.000998	CcSEcCtD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—bone cancer	8.78e-05	0.00232	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—RB1—bone cancer	8.78e-05	0.00232	CbGpPWpGaD
Temsirolimus—MTOR—LKB1 signaling events—TP53—bone cancer	8.77e-05	0.00232	CbGpPWpGaD
Temsirolimus—Pharyngitis—Doxorubicin—bone cancer	8.74e-05	0.000988	CcSEcCtD
Temsirolimus—MTOR—ErbB Signaling Pathway—EGFR—bone cancer	8.7e-05	0.0023	CbGpPWpGaD
Temsirolimus—Urinary tract disorder—Doxorubicin—bone cancer	8.69e-05	0.000983	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—bone cancer	8.67e-05	0.000981	CcSEcCtD
Temsirolimus—Dysgeusia—Methotrexate—bone cancer	8.67e-05	0.00098	CcSEcCtD
Temsirolimus—CYP3A7—Biological oxidations—CYP3A4—bone cancer	8.66e-05	0.00229	CbGpPWpGaD
Temsirolimus—Connective tissue disorder—Doxorubicin—bone cancer	8.65e-05	0.000978	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—bone cancer	8.63e-05	0.000976	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—bone cancer	8.63e-05	0.000976	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—bone cancer	8.59e-05	0.000972	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—bone cancer	8.57e-05	0.00097	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—bone cancer	8.56e-05	0.000968	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—EZH2—bone cancer	8.55e-05	0.00226	CbGpPWpGaD
Temsirolimus—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	8.54e-05	0.00225	CbGpPWpGaD
Temsirolimus—Chills—Epirubicin—bone cancer	8.54e-05	0.000966	CcSEcCtD
Temsirolimus—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.38e-05	0.00221	CbGpPWpGaD
Temsirolimus—Vomiting—Cisplatin—bone cancer	8.37e-05	0.000947	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—bone cancer	8.33e-05	0.000943	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—bone cancer	8.32e-05	0.000941	CcSEcCtD
Temsirolimus—Rash—Cisplatin—bone cancer	8.3e-05	0.000939	CcSEcCtD
Temsirolimus—Dermatitis—Cisplatin—bone cancer	8.29e-05	0.000938	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—EGFR—bone cancer	8.28e-05	0.00219	CbGpPWpGaD
Temsirolimus—Malnutrition—Epirubicin—bone cancer	8.28e-05	0.000937	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—bone cancer	8.28e-05	0.000937	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.24e-05	0.00218	CbGpPWpGaD
Temsirolimus—Eye disorder—Doxorubicin—bone cancer	8.23e-05	0.000931	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—bone cancer	8.18e-05	0.000925	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—bone cancer	8.17e-05	0.000924	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—bone cancer	8.11e-05	0.000917	CcSEcCtD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—bone cancer	8.08e-05	0.00213	CbGpPWpGaD
Temsirolimus—Back pain—Epirubicin—bone cancer	8.01e-05	0.000906	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—bone cancer	7.99e-05	0.000903	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—bone cancer	7.95e-05	0.000899	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.95e-05	0.0021	CbGpPWpGaD
Temsirolimus—Mediastinal disorder—Doxorubicin—bone cancer	7.93e-05	0.000897	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—bone cancer	7.92e-05	0.000896	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—MDM2—bone cancer	7.91e-05	0.00209	CbGpPWpGaD
Temsirolimus—Chills—Doxorubicin—bone cancer	7.9e-05	0.000893	CcSEcCtD
Temsirolimus—Nausea—Cisplatin—bone cancer	7.82e-05	0.000884	CcSEcCtD
Temsirolimus—Cough—Methotrexate—bone cancer	7.72e-05	0.000874	CcSEcCtD
Temsirolimus—MTOR—PI3K/AKT activation—MDM2—bone cancer	7.72e-05	0.00204	CbGpPWpGaD
Temsirolimus—Mental disorder—Doxorubicin—bone cancer	7.71e-05	0.000872	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—bone cancer	7.67e-05	0.000867	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—bone cancer	7.66e-05	0.000867	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—bone cancer	7.66e-05	0.000867	CcSEcCtD
Temsirolimus—MTOR—GAB1 signalosome—MDM2—bone cancer	7.66e-05	0.00202	CbGpPWpGaD
Temsirolimus—Anaemia—Epirubicin—bone cancer	7.65e-05	0.000866	CcSEcCtD
Temsirolimus—MTOR—CXCR4-mediated signaling events—MMP9—bone cancer	7.56e-05	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—bone cancer	7.55e-05	0.00199	CbGpPWpGaD
Temsirolimus—Arthralgia—Methotrexate—bone cancer	7.53e-05	0.000852	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—bone cancer	7.53e-05	0.000852	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—bone cancer	7.53e-05	0.000852	CcSEcCtD
Temsirolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	7.53e-05	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KIT—bone cancer	7.51e-05	0.00198	CbGpPWpGaD
Temsirolimus—Dysgeusia—Doxorubicin—bone cancer	7.5e-05	0.000849	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—ATF1—bone cancer	7.49e-05	0.00198	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—bone cancer	7.48e-05	0.00198	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—bone cancer	7.48e-05	0.00198	CbGpPWpGaD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.48e-05	0.000846	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—bone cancer	7.41e-05	0.000839	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—bone cancer	7.41e-05	0.000838	CcSEcCtD
Temsirolimus—CYP3A7—Biological oxidations—GSTP1—bone cancer	7.4e-05	0.00196	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—bone cancer	7.31e-05	0.00193	CbGpPWpGaD
Temsirolimus—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	7.3e-05	0.00193	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—EGFR—bone cancer	7.24e-05	0.00191	CbGpPWpGaD
Temsirolimus—Cough—Epirubicin—bone cancer	7.23e-05	0.000817	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—bone cancer	7.22e-05	0.000817	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KIT—bone cancer	7.18e-05	0.0019	CbGpPWpGaD
Temsirolimus—Convulsion—Epirubicin—bone cancer	7.18e-05	0.000812	CcSEcCtD
Temsirolimus—Infection—Methotrexate—bone cancer	7.17e-05	0.000812	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.17e-05	0.00189	CbGpPWpGaD
Temsirolimus—Hypertension—Epirubicin—bone cancer	7.15e-05	0.000809	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—bone cancer	7.08e-05	0.000801	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—bone cancer	7.08e-05	0.000801	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—bone cancer	7.07e-05	0.0008	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—KIT—bone cancer	7.07e-05	0.00187	CbGpPWpGaD
Temsirolimus—Arthralgia—Epirubicin—bone cancer	7.05e-05	0.000798	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—bone cancer	7.05e-05	0.000798	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—bone cancer	7.05e-05	0.000798	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—bone cancer	7.03e-05	0.000795	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—bone cancer	7.02e-05	0.000794	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	7e-05	0.000792	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—bone cancer	6.95e-05	0.00184	CbGpPWpGaD
Temsirolimus—Anorexia—Methotrexate—bone cancer	6.88e-05	0.000779	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—bone cancer	6.86e-05	0.000776	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—bone cancer	6.76e-05	0.000765	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—bone cancer	6.76e-05	0.000765	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—KIT—bone cancer	6.75e-05	0.00178	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KIT—bone cancer	6.72e-05	0.00177	CbGpPWpGaD
Temsirolimus—Infection—Epirubicin—bone cancer	6.71e-05	0.00076	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—bone cancer	6.69e-05	0.000756	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—KIT—bone cancer	6.68e-05	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—BRAF—bone cancer	6.68e-05	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—GSTP1—bone cancer	6.66e-05	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KIT—bone cancer	6.65e-05	0.00176	CbGpPWpGaD
Temsirolimus—Convulsion—Doxorubicin—bone cancer	6.64e-05	0.000751	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—bone cancer	6.63e-05	0.00075	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—bone cancer	6.62e-05	0.000749	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—bone cancer	6.62e-05	0.000748	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—bone cancer	6.58e-05	0.000744	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—bone cancer	6.56e-05	0.000743	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—RB1—bone cancer	6.56e-05	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	6.55e-05	0.00173	CbGpPWpGaD
Temsirolimus—Insomnia—Methotrexate—bone cancer	6.53e-05	0.000739	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—bone cancer	6.52e-05	0.000738	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—bone cancer	6.52e-05	0.000738	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—bone cancer	6.52e-05	0.000738	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—JUN—bone cancer	6.5e-05	0.00172	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—JUN—bone cancer	6.5e-05	0.00172	CbGpPWpGaD
Temsirolimus—Anxiety—Doxorubicin—bone cancer	6.5e-05	0.000735	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.48e-05	0.000733	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—bone cancer	6.44e-05	0.000729	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—bone cancer	6.44e-05	0.000728	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—bone cancer	6.42e-05	0.000726	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR—BRAF—bone cancer	6.31e-05	0.00167	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—bone cancer	6.31e-05	0.00167	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—bone cancer	6.3e-05	0.00166	CbGpPWpGaD
Temsirolimus—Decreased appetite—Methotrexate—bone cancer	6.28e-05	0.00071	CcSEcCtD
Temsirolimus—CYP3A5—Biological oxidations—CYP3A4—bone cancer	6.26e-05	0.00165	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KIT—bone cancer	6.26e-05	0.00165	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	6.26e-05	0.00165	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KIT—bone cancer	6.26e-05	0.00165	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Doxorubicin—bone cancer	6.25e-05	0.000707	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—bone cancer	6.25e-05	0.000707	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—bone cancer	6.24e-05	0.000705	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—bone cancer	6.23e-05	0.000704	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—bone cancer	6.21e-05	0.000703	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—KIT—bone cancer	6.2e-05	0.00164	CbGpPWpGaD
Temsirolimus—Pain—Methotrexate—bone cancer	6.18e-05	0.000699	CcSEcCtD
Temsirolimus—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	6.17e-05	0.00163	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.16e-05	0.00163	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—bone cancer	6.16e-05	0.000697	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KIT—bone cancer	6.15e-05	0.00162	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Doxorubicin—bone cancer	6.13e-05	0.000694	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—bone cancer	6.12e-05	0.000693	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—KIT—bone cancer	6.12e-05	0.00162	CbGpPWpGaD
Temsirolimus—Insomnia—Epirubicin—bone cancer	6.11e-05	0.000691	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—bone cancer	6.07e-05	0.000687	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—bone cancer	6.03e-05	0.000682	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—bone cancer	6.01e-05	0.00068	CcSEcCtD
Temsirolimus—MTOR—AMPK Signaling—TP53—bone cancer	6.01e-05	0.00159	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bone cancer	6e-05	0.00158	CbGpPWpGaD
Temsirolimus—Anorexia—Doxorubicin—bone cancer	5.96e-05	0.000674	CcSEcCtD
Temsirolimus—ABCB1—bone marrow—bone cancer	5.92e-05	0.0061	CbGeAlD
Temsirolimus—MTOR—Signaling by SCF-KIT—MDM2—bone cancer	5.91e-05	0.00156	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Methotrexate—bone cancer	5.91e-05	0.000668	CcSEcCtD
Temsirolimus—ABCB1—spinal cord—bone cancer	5.9e-05	0.00608	CbGeAlD
Temsirolimus—MTOR—Signaling by FGFR in disease—BRAF—bone cancer	5.88e-05	0.00155	CbGpPWpGaD
Temsirolimus—Decreased appetite—Epirubicin—bone cancer	5.88e-05	0.000665	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—bone cancer	5.83e-05	0.00066	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—bone cancer	5.83e-05	0.000659	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—KIT—bone cancer	5.79e-05	0.00153	CbGpPWpGaD
Temsirolimus—Constipation—Epirubicin—bone cancer	5.78e-05	0.000654	CcSEcCtD
Temsirolimus—Pain—Epirubicin—bone cancer	5.78e-05	0.000654	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—bone cancer	5.71e-05	0.000646	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—bone cancer	5.71e-05	0.000646	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.7e-05	0.000645	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—bone cancer	5.66e-05	0.00064	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—MDM2—bone cancer	5.66e-05	0.00149	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.63e-05	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—bone cancer	5.6e-05	0.00148	CbGpPWpGaD
Temsirolimus—Dyspnoea—Doxorubicin—bone cancer	5.58e-05	0.000631	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—MDM2—bone cancer	5.57e-05	0.00147	CbGpPWpGaD
Temsirolimus—Somnolence—Doxorubicin—bone cancer	5.56e-05	0.000629	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	5.54e-05	0.00146	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Epirubicin—bone cancer	5.53e-05	0.000625	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—RGS1—bone cancer	5.51e-05	0.00145	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GRM4—bone cancer	5.51e-05	0.00145	CbGpPWpGaD
Temsirolimus—Decreased appetite—Doxorubicin—bone cancer	5.44e-05	0.000615	CcSEcCtD
Temsirolimus—MTOR—PI-3K cascade—EGFR—bone cancer	5.4e-05	0.00143	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—bone cancer	5.4e-05	0.000611	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—bone cancer	5.39e-05	0.00061	CcSEcCtD
Temsirolimus—CYP3A5—Biological oxidations—GSTP1—bone cancer	5.35e-05	0.00141	CbGpPWpGaD
Temsirolimus—Constipation—Doxorubicin—bone cancer	5.35e-05	0.000605	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—bone cancer	5.35e-05	0.000605	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—bone cancer	5.34e-05	0.000604	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—bone cancer	5.34e-05	0.000604	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—bone cancer	5.32e-05	0.000602	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—MDM2—bone cancer	5.32e-05	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—MDM2—bone cancer	5.29e-05	0.0014	CbGpPWpGaD
Temsirolimus—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	5.28e-05	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—EGFR—bone cancer	5.28e-05	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—MDM2—bone cancer	5.26e-05	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—MDM2—bone cancer	5.24e-05	0.00138	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.24e-05	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—EGFR—bone cancer	5.23e-05	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	5.21e-05	0.00138	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NDUFA12—bone cancer	5.19e-05	0.00137	CbGpPWpGaD
Temsirolimus—Asthenia—Methotrexate—bone cancer	5.18e-05	0.000586	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	5.16e-05	0.00136	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Doxorubicin—bone cancer	5.11e-05	0.000578	CcSEcCtD
Temsirolimus—MTOR—ErbB1 downstream signaling—EGFR—bone cancer	5.11e-05	0.00135	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	5.11e-05	0.00135	CbGpPWpGaD
Temsirolimus—Pruritus—Methotrexate—bone cancer	5.11e-05	0.000578	CcSEcCtD
Temsirolimus—FKBP1A—Disease—ENO2—bone cancer	5.07e-05	0.00134	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—JUN—bone cancer	5.05e-05	0.00133	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—MMP9—bone cancer	5e-05	0.00132	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Epirubicin—bone cancer	4.98e-05	0.000563	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—bone cancer	4.94e-05	0.000559	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—bone cancer	4.94e-05	0.000559	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—bone cancer	4.94e-05	0.000559	CcSEcCtD
Temsirolimus—MTOR—DAP12 interactions—MDM2—bone cancer	4.93e-05	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	4.93e-05	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—MDM2—bone cancer	4.93e-05	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—MDM2—bone cancer	4.88e-05	0.00129	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—JUN—bone cancer	4.86e-05	0.00128	CbGpPWpGaD
Temsirolimus—Asthenia—Epirubicin—bone cancer	4.85e-05	0.000549	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—MDM2—bone cancer	4.84e-05	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CDK4—bone cancer	4.83e-05	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—MDM2—bone cancer	4.82e-05	0.00127	CbGpPWpGaD
Temsirolimus—Pruritus—Epirubicin—bone cancer	4.78e-05	0.000541	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—bone cancer	4.78e-05	0.00054	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—GRM1—bone cancer	4.77e-05	0.00126	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.77e-05	0.00126	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.73e-05	0.00125	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—DHFR—bone cancer	4.7e-05	0.00124	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—JUN—bone cancer	4.64e-05	0.00123	CbGpPWpGaD
Temsirolimus—Diarrhoea—Epirubicin—bone cancer	4.62e-05	0.000523	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—bone cancer	4.61e-05	0.000521	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—bone cancer	4.6e-05	0.00121	CbGpPWpGaD
Temsirolimus—Vomiting—Methotrexate—bone cancer	4.59e-05	0.000519	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—MDM2—bone cancer	4.56e-05	0.0012	CbGpPWpGaD
Temsirolimus—Rash—Methotrexate—bone cancer	4.55e-05	0.000515	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—bone cancer	4.55e-05	0.000515	CcSEcCtD
Temsirolimus—Headache—Methotrexate—bone cancer	4.52e-05	0.000512	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—bone cancer	4.49e-05	0.000508	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—bone cancer	4.47e-05	0.000506	CcSEcCtD
Temsirolimus—CYP2D6—Biological oxidations—CYP3A4—bone cancer	4.45e-05	0.00118	CbGpPWpGaD
Temsirolimus—Pruritus—Doxorubicin—bone cancer	4.42e-05	0.0005	CcSEcCtD
Temsirolimus—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	4.39e-05	0.00116	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	4.36e-05	0.00115	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.34e-05	0.00115	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NT5C3A—bone cancer	4.3e-05	0.00114	CbGpPWpGaD
Temsirolimus—Vomiting—Epirubicin—bone cancer	4.3e-05	0.000486	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bone cancer	4.29e-05	0.00113	CbGpPWpGaD
Temsirolimus—Nausea—Methotrexate—bone cancer	4.29e-05	0.000485	CcSEcCtD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.28e-05	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	4.28e-05	0.00113	CbGpPWpGaD
Temsirolimus—Diarrhoea—Doxorubicin—bone cancer	4.28e-05	0.000484	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—ATF1—bone cancer	4.27e-05	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KIT—bone cancer	4.26e-05	0.00113	CbGpPWpGaD
Temsirolimus—Rash—Epirubicin—bone cancer	4.26e-05	0.000482	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—bone cancer	4.26e-05	0.000482	CcSEcCtD
Temsirolimus—Headache—Epirubicin—bone cancer	4.23e-05	0.000479	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—RB1—bone cancer	4.2e-05	0.00111	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—bone cancer	4.14e-05	0.000468	CcSEcCtD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.06e-05	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—bone cancer	4.04e-05	0.00107	CbGpPWpGaD
Temsirolimus—Nausea—Epirubicin—bone cancer	4.01e-05	0.000454	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—BRAF—bone cancer	4.01e-05	0.00106	CbGpPWpGaD
Temsirolimus—Vomiting—Doxorubicin—bone cancer	3.98e-05	0.00045	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—bone cancer	3.94e-05	0.000446	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—bone cancer	3.94e-05	0.000446	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—bone cancer	3.92e-05	0.000443	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bone cancer	3.86e-05	0.00102	CbGpPWpGaD
Temsirolimus—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.84e-05	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bone cancer	3.82e-05	0.00101	CbGpPWpGaD
Temsirolimus—CYP2D6—Biological oxidations—GSTP1—bone cancer	3.81e-05	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—bone cancer	3.8e-05	0.001	CbGpPWpGaD
Temsirolimus—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	3.75e-05	0.000991	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NDUFA12—bone cancer	3.75e-05	0.000991	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—bone cancer	3.71e-05	0.00042	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—bone cancer	3.63e-05	0.000959	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.63e-05	0.000959	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.62e-05	0.000956	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—bone cancer	3.61e-05	0.000955	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bone cancer	3.61e-05	0.000955	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—bone cancer	3.6e-05	0.00095	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—EGFR—bone cancer	3.58e-05	0.000945	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—MDM2—bone cancer	3.58e-05	0.000945	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	3.53e-05	0.000932	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFBR2—bone cancer	3.41e-05	0.0009	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—bone cancer	3.37e-05	0.000889	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	3.37e-05	0.000889	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—bone cancer	3.37e-05	0.000889	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMO—bone cancer	3.36e-05	0.000888	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—MDM2—bone cancer	3.36e-05	0.000886	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—bone cancer	3.34e-05	0.000881	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bone cancer	3.31e-05	0.000873	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—bone cancer	3.29e-05	0.00087	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bone cancer	3.21e-05	0.000848	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.13e-05	0.000825	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—bone cancer	3.12e-05	0.000823	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—JUN—bone cancer	3.11e-05	0.000821	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NT5C3A—bone cancer	3.11e-05	0.000821	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RGS1—bone cancer	3.1e-05	0.000818	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GRM4—bone cancer	3.1e-05	0.000818	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—GNA11—bone cancer	3.08e-05	0.000812	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	2.98e-05	0.000788	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ATF1—bone cancer	2.86e-05	0.000755	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ENO2—bone cancer	2.85e-05	0.000753	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NDUFA12—bone cancer	2.83e-05	0.000748	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL3—bone cancer	2.79e-05	0.000737	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.69e-05	0.000711	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GRM1—bone cancer	2.69e-05	0.000709	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NDUFA12—bone cancer	2.67e-05	0.000704	CbGpPWpGaD
Temsirolimus—MTOR—Disease—DHFR—bone cancer	2.64e-05	0.000698	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.49e-05	0.000657	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ATF1—bone cancer	2.49e-05	0.000657	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.45e-05	0.000648	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KIT—bone cancer	2.43e-05	0.000642	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL3—bone cancer	2.43e-05	0.000641	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFBR2—bone cancer	2.39e-05	0.00063	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NT5C3A—bone cancer	2.35e-05	0.000619	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KIT—bone cancer	2.33e-05	0.000616	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KIT—bone cancer	2.32e-05	0.000614	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—bone cancer	2.29e-05	0.000606	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IGF1R—bone cancer	2.24e-05	0.000593	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NT5C3A—bone cancer	2.21e-05	0.000584	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—BRAF—bone cancer	2.18e-05	0.000577	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—bone cancer	2.05e-05	0.000542	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2e-05	0.000527	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.92e-05	0.000508	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFBR2—bone cancer	1.92e-05	0.000506	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—MDM2—bone cancer	1.91e-05	0.000506	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMO—bone cancer	1.89e-05	0.0005	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—bone cancer	1.88e-05	0.000497	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—MDM2—bone cancer	1.84e-05	0.000486	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MDM2—bone cancer	1.83e-05	0.000483	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—bone cancer	1.76e-05	0.000466	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—DHFR—bone cancer	1.75e-05	0.000461	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NDUFA12—bone cancer	1.74e-05	0.000461	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.74e-05	0.000458	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—GNA11—bone cancer	1.73e-05	0.000457	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—JUN—bone cancer	1.66e-05	0.000439	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GNA11—bone cancer	1.63e-05	0.000431	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KIT—bone cancer	1.63e-05	0.00043	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ATF1—bone cancer	1.61e-05	0.000425	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL3—bone cancer	1.57e-05	0.000414	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—BRAF—bone cancer	1.53e-05	0.000404	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP3A4—bone cancer	1.48e-05	0.000391	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NT5C3A—bone cancer	1.45e-05	0.000382	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KIT—bone cancer	1.42e-05	0.000374	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.36e-05	0.00036	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—bone cancer	1.36e-05	0.00036	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFBR2—bone cancer	1.34e-05	0.000354	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—bone cancer	1.31e-05	0.000346	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KIT—bone cancer	1.31e-05	0.000345	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MDM2—bone cancer	1.28e-05	0.000339	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTP1—bone cancer	1.27e-05	0.000334	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—DHFR—bone cancer	1.26e-05	0.000334	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1R—bone cancer	1.26e-05	0.000333	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—bone cancer	1.26e-05	0.000332	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—bone cancer	1.25e-05	0.00033	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—bone cancer	1.23e-05	0.000324	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GNA11—bone cancer	1.18e-05	0.000312	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.15e-05	0.000302	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MDM2—bone cancer	1.12e-05	0.000294	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—JUN—bone cancer	1.11e-05	0.000294	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—bone cancer	1.08e-05	0.000286	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP3A4—bone cancer	1.07e-05	0.000283	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MDM2—bone cancer	1.03e-05	0.000272	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—bone cancer	1.03e-05	0.000271	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—bone cancer	9.93e-06	0.000262	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—bone cancer	9.69e-06	0.000256	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—bone cancer	9.68e-06	0.000256	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—DHFR—bone cancer	9.53e-06	0.000252	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—bone cancer	9.15e-06	0.000242	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—bone cancer	9.15e-06	0.000242	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—DHFR—bone cancer	8.98e-06	0.000237	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GNA11—bone cancer	8.91e-06	0.000235	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—bone cancer	8.76e-06	0.000231	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—bone cancer	8.6e-06	0.000227	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GNA11—bone cancer	8.39e-06	0.000222	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP3A4—bone cancer	8.08e-06	0.000213	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—bone cancer	7.62e-06	0.000201	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP3A4—bone cancer	7.61e-06	0.000201	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—bone cancer	7.36e-06	0.000194	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—bone cancer	7.21e-06	0.00019	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—bone cancer	7.04e-06	0.000186	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—bone cancer	6.91e-06	0.000182	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—bone cancer	6.56e-06	0.000173	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—bone cancer	6.51e-06	0.000172	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—bone cancer	6.33e-06	0.000167	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—bone cancer	6.27e-06	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—bone cancer	6.1e-06	0.000161	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—DHFR—bone cancer	5.87e-06	0.000155	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GNA11—bone cancer	5.49e-06	0.000145	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—bone cancer	4.93e-06	0.00013	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—bone cancer	4.74e-06	0.000125	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—bone cancer	4.26e-06	0.000112	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—bone cancer	4.14e-06	0.000109	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—bone cancer	3.58e-06	9.45e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—bone cancer	3.37e-06	8.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—bone cancer	2.2e-06	5.82e-05	CbGpPWpGaD
